Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today)

Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today)

With the end of 2005 less than two weeks away, the biggest collaborative biotech deal of the year came in just under the wire. (BioWorld Today)

With the end of 2005 less than two weeks away, the biggest collaborative biotech deal of the year came in just under the wire. (BioWorld Today)